{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:32Z","timestamp":1786984352819,"version":"build-2736575974"},"reference-count":156,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01AA030180"],"award-info":[{"award-number":["5R01AA030180"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RO1CA164719"],"award-info":[{"award-number":["RO1CA164719"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA 016059"],"award-info":[{"award-number":["P30 CA 016059"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["2R56DK115377-05A1"],"award-info":[{"award-number":["2R56DK115377-05A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK139587"],"award-info":[{"award-number":["R01DK139587"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1P01CA275740"],"award-info":[{"award-number":["1P01CA275740"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["5I01BX005730"],"award-info":[{"award-number":["5I01BX005730"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK6BX004477"],"award-info":[{"award-number":["IK6BX004477"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1 IS1 BX004777-01"],"award-info":[{"award-number":["1 IS1 BX004777-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1IS1BX005517-01"],"award-info":[{"award-number":["1IS1BX005517-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ajpath.2024.11.004","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T18:57:01Z","timestamp":1734634621000},"page":"397-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Gut Microbiome and Bile Acid Interactions"],"prefix":"10.1016","volume":"195","author":[{"given":"Nan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareh","family":"Bayatpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip B.","family":"Hylemon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3234-1769","authenticated-orcid":false,"given":"Sayed O.","family":"Aseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1765-0002","authenticated-orcid":false,"given":"Paul J.","family":"Brindley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-372X","authenticated-orcid":false,"given":"Huiping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2024.11.004_bib1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.21614\/chirurgia.2023.v.118.i.6.p.553","article-title":"Intrahepatic cholangiocarcinoma - where do we stand today? literature review","volume":"118","author":"Savin","year":"2023","journal-title":"Chirurgia (Bucur)"},{"key":"10.1016\/j.ajpath.2024.11.004_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ajpath.2024.11.004_bib3","article-title":"Bile acids regulation of cellular stress responses in liver physiology and diseases","volume":"2","author":"Tiangang","year":"2024","journal-title":"eGastroenterology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41575-024-00896-2","article-title":"Another renaissance for bile acid gastrointestinal microbiology","volume":"21","author":"Ridlon","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.27085","article-title":"Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2","volume":"60","author":"Liu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib7","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.ajpath.2018.05.015","article-title":"Conjugated bile acids promote invasive growth of esophageal adenocarcinoma cells and cancer stem cell expansion via sphingosine 1-phosphate receptor 2-mediated yes-associated protein activation","volume":"188","author":"Liu","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib8","doi-asserted-by":"crossref","first-page":"30988","DOI":"10.1074\/jbc.M115.668277","article-title":"Taurocholate induces cyclooxygenase-2 expression via the sphingosine 1-phosphate receptor 2 in a human cholangiocarcinoma cell line","volume":"290","author":"Liu","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.11.004_bib9","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1245\/s10434-022-12806-4","article-title":"Conjugated bile acids accelerate progression of pancreatic cancer metastasis via S1PR2 signaling in cholestasis","volume":"30","author":"Sarkar","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib10","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.29076","article-title":"The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/164_2019_230","article-title":"Bile acid-activated receptors: GPBAR1 (TGR5) and other g protein-coupled receptors","volume":"256","author":"Keitel","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.11.004_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2024.11.004_bib14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cells10020210","article-title":"Berberine prevents disease progression of nonalcoholic steatohepatitis through modulating multiple pathways","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2024.11.004_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13578-024-01195-8","article-title":"Therapeutic potential of berberine in attenuating cholestatic liver injury: insights from a PSC mouse model","volume":"14","author":"Wang","year":"2024","journal-title":"Cell Biosci"},{"key":"10.1016\/j.ajpath.2024.11.004_bib16","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2024.11.004_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bpg.2015.02.003","article-title":"Epidemiology of cholangiocarcinoma","volume":"29","author":"Bergquist","year":"2015","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/ijms25010461","article-title":"Molecular profile of intrahepatic cholangiocarcinoma","volume":"25","author":"Andraus","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2024.11.004_bib20","article-title":"Up-to-date pathologic classification and molecular characteristics of intrahepatic cholangiocarcinoma","volume":"9","author":"Chung","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ajpath.2024.11.004_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(00)80421-3","article-title":"Chronic cholestatic diseases","volume":"32","author":"Poupon","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib24","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"Ali","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"Bergquist","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","article-title":"Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience","volume":"24","author":"Chapman","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis","volume":"50","author":"Claessen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib29","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1007\/s00261-017-1328-8","article-title":"Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis","volume":"42","author":"Lee","year":"2017","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.ajpath.2024.11.004_bib30","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2023-100029","article-title":"New horizons of human genetics in digestive diseases","volume":"1","author":"Chen","year":"2023","journal-title":"eGastroenterology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1034\/j.1600-0676.2001.021004247.x","article-title":"Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis","volume":"21","author":"Oswald","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.ajpath.2024.11.004_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000212990","article-title":"Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 gene (MRP2\/ABCC2) with susceptibility to bile duct cancer","volume":"80","author":"Hoblinger","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.ajpath.2024.11.004_bib34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3347\/kjp.2017.55.3.295","article-title":"Subsets of inflammatory cytokine gene polymorphisms are associated with risk of carcinogenic liver fluke opisthorchis viverrini-associated advanced periductal fibrosis and cholangiocarcinoma","volume":"55","author":"Surapaitoon","year":"2017","journal-title":"Korean J Parasitol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0168-8278(99)80068-3","article-title":"Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis","volume":"30","author":"Bernal","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1440-1746.1993.tb01193.x","article-title":"Liver transplantation for primary sclerosing cholangitis versus primary biliary cirrhosis: a comparison of complications and outcome","volume":"8","author":"Strasser","year":"1993","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib37","first-page":"266","article-title":"Primary biliary cirrhosis and primary sclerosing cholangitis: a review featuring a women's health perspective","volume":"2","author":"Marchioni Beery","year":"2014","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib38","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1089-3261(03)00100-4","article-title":"Natural history of primary biliary cirrhosis","volume":"7","author":"Pares","year":"2003","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ajpath.2024.11.004_bib39","first-page":"442","article-title":"Cholangiocarcinoma associated with biliary cirrhosis due to congenital biliary atresia","volume":"131","author":"Kulkarni","year":"1977","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.ajpath.2024.11.004_bib40","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1023\/A:1018831903371","article-title":"Primary biliary cirrhosis associated with cholangiocarcinoma","volume":"43","author":"Akisawa","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ajpath.2024.11.004_bib41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.cgh.2007.05.020","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study","volume":"5","author":"Welzel","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib42","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200853","article-title":"Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma","volume":"218","author":"Paillet","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.ajpath.2024.11.004_bib43","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000218","article-title":"Distinct immune surveillance in primary biliary cholangitis and primary sclerosing cholangitis is linked with discrete cholangiocarcinoma risk","volume":"7","author":"Nanjundappa","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2024.11.004_bib44","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.3748\/wjg.v18.i48.7378","article-title":"Effect of dietary fiber on constipation: a meta analysis","volume":"18","author":"Yang","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiae085","article-title":"Comprehensive analysis of immune signatures in primary biliary cholangitis and autoimmune hepatitis","author":"Yang","year":"2024","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib46","first-page":"1","article-title":"Cancer review: cholangiocarcinoma","volume":"14","author":"Ghouri","year":"2015","journal-title":"J Carcinog"},{"key":"10.1016\/j.ajpath.2024.11.004_bib47","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4254\/wjh.v8.i26.1093","article-title":"Cholangiocarcinoma, gone without the Wnt?","volume":"8","author":"Noll","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/bs.acr.2022.02.001","article-title":"Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention","volume":"156","author":"Cadamuro","year":"2022","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.004_bib49","first-page":"184","article-title":"Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism","volume":"60","author":"Jaiswal","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.004_bib50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/gast.2001.20875","article-title":"Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes","volume":"120","author":"Jaiswal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib51","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/hep.510300522","article-title":"Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line","volume":"30","author":"Park","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib52","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2024.11.004_bib53","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/hep.27687","article-title":"IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism","volume":"61","author":"Yamada","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/s-2007-1007153","article-title":"Dysregulation of apoptosis in the cholangiopathies and cholangiocarcinoma","volume":"18","author":"Celli","year":"1998","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ajpath.2024.11.004_bib55","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.molcel.2015.01.018","article-title":"Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death","volume":"57","author":"Ichim","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.ajpath.2024.11.004_bib56","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.molcel.2015.03.003","article-title":"Caspase-3 promotes genetic instability and carcinogenesis","volume":"58","author":"Liu","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.ajpath.2024.11.004_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2796.2001.00775.x","article-title":"Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma","volume":"249","author":"Bergquist","year":"2001","journal-title":"J Intern Med"},{"key":"10.1016\/j.ajpath.2024.11.004_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-0031-1276646","article-title":"Genetics of hepatobiliary carcinogenesis","volume":"31","author":"Nault","year":"2011","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ajpath.2024.11.004_bib59","doi-asserted-by":"crossref","first-page":"G129","DOI":"10.1152\/ajpgi.00242.2005","article-title":"Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells","volume":"290","author":"Ishimura","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib60","doi-asserted-by":"crossref","first-page":"10895","DOI":"10.1073\/pnas.0802702105","article-title":"Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease","volume":"105","author":"Takeda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2024.11.004_bib61","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1038\/onc.2010.242","article-title":"TRAIL treatment provokes mutations in surviving cells","volume":"29","author":"Lovric","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2024.11.004_bib62","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ajpath.2014.10.027","article-title":"Functional role of cellular senescence in biliary injury","volume":"185","author":"Meng","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib63","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/hep.26993","article-title":"Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis","volume":"59","author":"Tabibian","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib64","doi-asserted-by":"crossref","first-page":"29568","DOI":"10.1074\/jbc.M603307200","article-title":"Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence","volume":"281","author":"Coppe","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.11.004_bib65","doi-asserted-by":"crossref","first-page":"12072","DOI":"10.1073\/pnas.211053698","article-title":"Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging","volume":"98","author":"Krtolica","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2024.11.004_bib66","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jhep.2012.10.011","article-title":"The dynamic biliary epithelia: molecules, pathways, and disease","volume":"58","author":"O'Hara","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib67","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/cells12050792","article-title":"Bile acids and biliary fibrosis","volume":"12","author":"Aseem","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2024.11.004_bib68","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/hep.26762","article-title":"Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting","volume":"59","author":"Sirica","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib69","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1245\/s10434-010-1391-7","article-title":"Hepatic stellate cells accelerate the malignant behavior of cholangiocarcinoma cells","volume":"18","author":"Okabe","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib70","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.3390\/jcm11216498","article-title":"Cancer-associated fibroblasts in cholangiocarcinoma: current knowledge and possible implications for therapy","volume":"11","author":"Montori","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajpath.2024.11.004_bib71","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1053\/j.gastro.2004.04.062","article-title":"Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes","volume":"127","author":"Safadi","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib72","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.22813","article-title":"Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride","volume":"49","author":"Park","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib73","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1053\/j.gastro.2005.10.055","article-title":"Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners","volume":"130","author":"Radaeva","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib74","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2005.12.025","article-title":"Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC","volume":"45","author":"Melhem","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib75","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.2337\/dc09-S355","article-title":"Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration","volume":"32 Suppl 2","author":"Staels","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpath.2024.11.004_bib76","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.smj.0000208120.73327.db","article-title":"Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review","volume":"99","author":"Insull","year":"2006","journal-title":"South Med J"},{"key":"10.1016\/j.ajpath.2024.11.004_bib77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ajpath.2024.11.004_bib78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ajpath.2024.11.004_bib79","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/j.2040-4603.2013.tb00519.x","article-title":"Bile formation and secretion","volume":"3","author":"Boyer","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.livres.2017.05.001","article-title":"Bile acid metabolism and signaling in liver disease and therapy","volume":"1","author":"Chiang","year":"2017","journal-title":"Liver Res"},{"key":"10.1016\/j.ajpath.2024.11.004_bib81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.livres.2020.05.001","article-title":"Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis","volume":"4","author":"Chiang","year":"2020","journal-title":"Liver Res"},{"key":"10.1016\/j.ajpath.2024.11.004_bib82","doi-asserted-by":"crossref","first-page":"10918","DOI":"10.1074\/jbc.275.15.10918","article-title":"Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription","volume":"275","author":"Chiang","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.11.004_bib83","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2024.11.004_bib84","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ajpath.2024.11.004_bib85","doi-asserted-by":"crossref","first-page":"G979","DOI":"10.1152\/ajpgi.00370.2011","article-title":"Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice","volume":"302","author":"Cui","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib86","doi-asserted-by":"crossref","first-page":"G1134","DOI":"10.1152\/ajpgi.00079.2007","article-title":"Obstructive cholestasis induces TNF-alpha- and IL-1-mediated periportal downregulation of Bsep and zonal regulation of Ntcp, Oatp1a4, and Oatp1b2","volume":"293","author":"Donner","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib87","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.20594","article-title":"Cytokine-independent repression of rodent Ntcp in obstructive cholestasis","volume":"41","author":"Geier","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib88","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1194\/jlr.R900007-JLR200","article-title":"Bile acids as regulatory molecules","volume":"50","author":"Hylemon","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ajpath.2024.11.004_bib89","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/j.2040-4603.2022.tb00205.x","article-title":"gut microbiome and the road to fatty liver disease","volume":"12","author":"Hylemon","year":"2021","journal-title":"Compr Physiol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib90","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib91","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/thy.2007.0255","article-title":"Bile acids and the membrane bile acid receptor TGR5--connecting nutrition and metabolism","volume":"18","author":"Thomas","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.ajpath.2024.11.004_bib92","doi-asserted-by":"crossref","first-page":"29971","DOI":"10.1074\/jbc.M501931200","article-title":"The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition","volume":"280","author":"Duran-Sandoval","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.11.004_bib93","doi-asserted-by":"crossref","first-page":"10315","DOI":"10.1074\/jbc.M807317200","article-title":"An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-\/- mice","volume":"284","author":"van Dijk","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.11.004_bib94","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000324126","article-title":"The bile acid membrane receptor TGR5: a valuable metabolic target","volume":"29","author":"Pols","year":"2011","journal-title":"Dig Dis"},{"key":"10.1016\/j.ajpath.2024.11.004_bib95","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000450981","article-title":"Intestinal farnesoid X receptor and takeda G protein couple receptor 5 signaling in metabolic regulation","volume":"35","author":"Chiang","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.ajpath.2024.11.004_bib96","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib97","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile acids activated receptors regulate innate immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib98","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2172671","article-title":"Bile acids as modulators of gut microbiota composition and function","volume":"15","author":"Larabi","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2024.11.004_bib99","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstrom","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2024.11.004_bib100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3748\/wjg.v18.i9.923","article-title":"High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids","volume":"18","author":"Stenman","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib101","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2024.11.004_bib102","doi-asserted-by":"crossref","first-page":"333","DOI":"10.21037\/atm.2018.07.16","article-title":"Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids","volume":"6","author":"Danese","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ajpath.2024.11.004_bib103","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1477-2574.2011.00296.x","article-title":"Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma","volume":"13","author":"Hashim Abdalla","year":"2011","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ajpath.2024.11.004_bib104","doi-asserted-by":"crossref","first-page":"s87","DOI":"10.5604\/01.3001.0010.5501","article-title":"Bile acids and cancer: direct and environmental-dependent effects","volume":"16","author":"Di Ciaula","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib105","article-title":"Research progress of bile acids in cancer","volume":"11","author":"Fu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib106","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/jcsm.12798","article-title":"Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome","volume":"12","author":"Feng","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ajpath.2024.11.004_bib107","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hep.20294","article-title":"The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?","volume":"40","author":"Trauner","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib108","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/aps.2014.117","article-title":"FXR and liver carcinogenesis","volume":"36","author":"Huang","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ajpath.2024.11.004_bib109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1756-8722-4-41","article-title":"Impact of bile acids on the growth of human cholangiocarcinoma via FXR","volume":"4","author":"Dai","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib110","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bcp.2013.07.022","article-title":"Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition","volume":"86","author":"Vaquero","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib111","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s43556-021-00035-2","article-title":"Targeting farnesoid X receptor (FXR) for developing novel therapeutics against cancer","volume":"2","author":"Girisa","year":"2021","journal-title":"Mol Biomed"},{"key":"10.1016\/j.ajpath.2024.11.004_bib112","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbadis.2017.08.016","article-title":"Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression","volume":"1864","author":"Erice","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.ajpath.2024.11.004_bib113","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib114","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/07357907.2012.762781","article-title":"Bile acids affect the growth of human cholangiocarcinoma via NF-[kappa]B pathway","volume":"31","author":"Dai","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ajpath.2024.11.004_bib115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation in\u00a0vivo and in\u00a0vitro","volume":"65","author":"Reich","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2024.11.004_bib116","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.21037\/atm-21-2631","article-title":"TGR5 protects against cholestatic liver disease via suppressing the NF-kappaB pathway and activating the Nrf2\/HO-1 pathway","volume":"9","author":"Yang","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ajpath.2024.11.004_bib117","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/hep.20967","article-title":"Roles of AKT and sphingosine kinase in the antiapoptotic effects of bile duct ligation in mouse liver","volume":"42","author":"Osawa","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib118","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","article-title":"Metabolic reprogramming in cholangiocarcinoma","volume":"77","author":"Raggi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib119","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12935-019-1014-8","article-title":"Roles of sphingosine-1-phosphate signaling in cancer","volume":"19","author":"Wang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ajpath.2024.11.004_bib120","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1126\/science.aau5812","article-title":"The gut microbiota at the intersection of diet and human health","volume":"362","author":"Gentile","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2024.11.004_bib121","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.11.004_bib122","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4161\/gmic.25723","article-title":"Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship","volume":"4","author":"Ridlon","year":"2013","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2024.11.004_bib123","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib124","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.3390\/ijms24043817","article-title":"Inflammatory bowel diseases and gut microbiota","volume":"24","author":"Haneishi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2024.11.004_bib125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1172\/JCI108271","article-title":"Degradation of blood group antigens in human colon ecosystems, II: a gene interaction in man that affects the fecal population density of certain enteric bacteria","volume":"57","author":"Hoskins","year":"1976","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2024.11.004_bib126","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/gast.2000.16495","article-title":"Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis","volume":"119","author":"Thomas","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib127","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1053\/j.gastro.2011.07.046","article-title":"Bile acid is a host factor that regulates the composition of the cecal microbiota in rats","volume":"141","author":"Islam","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib128","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(23)00098-5","article-title":"Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED consortium","volume":"8","author":"Bajaj","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chembiol.2018.10.003","article-title":"Bile acid 7alpha-dehydroxylating gut bacteria secrete antibiotics that inhibit Clostridium difficile: role of secondary bile acids","volume":"26","author":"Kang","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib131","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3390\/cells12121576","article-title":"Relevance of bile acids in cholangiocarcinoma pathogenesis: critical revision and future directions","volume":"12","author":"Cossiga","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2024.11.004_bib132","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1194\/jlr.R069286","article-title":"The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases","volume":"57","author":"Nagahashi","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ajpath.2024.11.004_bib133","doi-asserted-by":"crossref","first-page":"G773","DOI":"10.1152\/ajpgi.00080.2019","article-title":"Cell-specific regulatory effects of CXCR2 on cholestatic liver injury","volume":"317","author":"Konishi","year":"2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib134","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antiox13010028","article-title":"Oxidative stress and redox-dependent pathways in cholangiocarcinoma","volume":"13","author":"Caligiuri","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.ajpath.2024.11.004_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2024.101951","article-title":"Intrahepatic cholangiocarcinoma biomarkers: towards early detection and personalized pharmacological treatments","volume":"73","author":"Capuozzo","year":"2024","journal-title":"Mol Cell Probes"},{"key":"10.1016\/j.ajpath.2024.11.004_bib136","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/ijms25010543","article-title":"Current and emerging therapeutic targets for the treatment of cholangiocarcinoma: an updated review","volume":"25","author":"Hadfield","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2024.11.004_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104235","article-title":"Immunotherapy and targeted therapy for cholangiocarcinoma: artificial intelligence research in imaging","volume":"194","author":"Liu","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib138","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11864-023-01153-5","article-title":"Current standards, multidisciplinary approaches, and future directions in the management of extrahepatic cholangiocarcinoma","volume":"25","author":"Wheless","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib139","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/hep.27223","article-title":"Cholangiocarcinoma development: the resurgence of bile acids","volume":"60","author":"Maroni","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib140","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/jcm12041683","article-title":"Research progress of fecal microbiota transplantation in liver diseases","volume":"12","author":"Zhao","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajpath.2024.11.004_bib141","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib142","doi-asserted-by":"crossref","first-page":"438","DOI":"10.14218\/JCTH.2018.00033","article-title":"Healthy donor fecal microbiota transplantation for recurrent bacterial cholangitis in primary sclerosing cholangitis - a single case report","volume":"6","author":"Philips","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib143","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000338834","article-title":"Successful treatment of primary sclerosing cholangitis with a steroid and a probiotic","volume":"6","author":"Shimizu","year":"2012","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib144","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","article-title":"Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study","volume":"20","author":"Vleggaar","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0039-1688501","article-title":"Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"Shah","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ajpath.2024.11.004_bib146","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","article-title":"Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial","volume":"40","author":"Farkkila","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib147","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","article-title":"Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis","volume":"55","author":"Ali","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib148","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3390\/biomedicines11061713","article-title":"Current therapies for cholestatic diseases","volume":"11","author":"Mendez-Sanchez","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ajpath.2024.11.004_bib149","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/gutjnl-2017-314553","article-title":"Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(-\/-) mice by modulating composition, signalling and excretion of faecal bile acids","volume":"67","author":"Fuchs","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2024.11.004_bib150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib151","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2024.11.004_bib152","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.004_bib153","article-title":"Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-\/-) mouse model of sclerosing cholangitis","volume":"5","author":"Fuchs","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ajpath.2024.11.004_bib154","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOG.0000000000000525","article-title":"Obeticholic acid in primary biliary cholangitis: where we stand","volume":"35","author":"Manne","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.11.004_bib155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210077","article-title":"The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma","volume":"14","author":"Di Matteo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2024.11.004_bib156","first-page":"5","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann Transl Med"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024004450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024004450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:23:45Z","timestamp":1778639025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944024004450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0002944024004450"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.11.004","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gut Microbiome and Bile Acid Interactions","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}